Genentech Receives FDA Approval for Tecentriq in Bladder Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy NTRA?
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Tecentriq and Tecentriq Hybreza as an adjuvant treatment for adult patients with muscle-invasive bladder cancer who have circulating tumor DNA molecular residual disease after cystectomy, as identified by Natera's (NTRA) Signatera CDx personalized MRD assay. "Combining our cancer immunotherapy Tecentriq with state-of-the-art MRD testing allows more precise identification of patients who are candidates for intervention and those who might safely avoid unnecessary treatment," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We look forward to delivering this first of its kind ctDNA-guided regulatory approval to bladder cancer physicians and patients in the U.S."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 186.360
Low
205.00
Averages
262.92
High
300.00
Current: 186.360
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves Tecentriq for Bladder Cancer Treatment
- New Indication Approved: The FDA has approved Roche-owned Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), specifically targeting those with circulating tumor DNA molecular residual disease after cystectomy, marking a significant expansion in cancer treatment applications.
- Companion Diagnostic Approved: The FDA also approved Natera's Signatera CDx as a companion diagnostic for this indication, aimed at identifying ctDNA MRD-positive patients who are likely to benefit from Tecentriq therapy, thereby enhancing treatment precision and effectiveness.
- Increased Indications: Tecentriq now boasts 11 approved indications, demonstrating its broad applicability in oncology and strengthening Roche's competitive position in the oncology market while providing patients with more treatment options.
- Positive Market Outlook: With the expansion of Tecentriq's indications, Roche's market outlook in oncology appears optimistic, expected to drive future sales growth and solidify its leadership position in the biopharmaceutical industry.
See More
Natera Receives FDA Approval for Personalized MRD Testing
- FDA Approval Milestone: Natera's Signatera CDx has received FDA approval as the first personalized molecular residual disease (MRD) test for MIBC patients, marking a new standard in precision cancer treatment that is expected to significantly improve outcomes for MRD-positive patients.
- Clinical Trial Support: The IMvigor011 trial demonstrated that MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival (DFS) and overall survival (OS), while MRD-negative patients had a 97% two-year OS without any adjuvant therapy, providing crucial evidence for clinical decision-making.
- Significant Market Potential: With approximately 30,000 new MIBC diagnoses annually in the U.S. and 150,000 globally, the application of Signatera will assist physicians in accurately identifying recurrence risks, optimizing treatment plans, and reducing unnecessary therapies, thereby enhancing patient quality of life.
- Signal of Industry Transformation: This approval not only validates Natera's decade-long vision but also propels the advancement of precision oncology, likely leading to the application of MRD testing across more cancer types, further improving patient treatment outcomes and survival rates.
See More
Natera Reports Q1 Results Exceeding Revenue Expectations with 38.8% Growth
- Significant Revenue Growth: Natera's Q1 revenue reached $696.6 million, reflecting a 38.8% year-over-year increase that surpassed analyst expectations of $613.9 million, indicating strong market demand in women's health and oncology sectors.
- GAAP Loss Exceeds Expectations: Despite robust revenue, Natera reported a GAAP loss of $0.60 per share, which was worse than the anticipated $0.55 loss, leading to a negative market reaction that impacted stock performance.
- Surge in Clinical Testing Demand: Clinical oncology testing volumes grew by 55% year-over-year, driven by strong demand for the Signatera product and increased physician adoption, highlighting the company's competitive position in the cancer detection market.
- Future Growth Potential: Natera plans to launch Signatera in Japan, which is expected to significantly expand its colorectal cancer testing market, while also investing in early detection platforms to drive long-term growth opportunities.
See More
Natera Reports 39% Revenue Growth in Q1 2026
- Significant Revenue Growth: Natera reported $697 million in revenue for Q1 2026, representing a 39% year-over-year increase, highlighting strong performance in women's health and oncology, which further solidifies its market position.
- Surge in Product Orders: The Fetal Focus product is approaching 200,000 orders, marking a successful launch in women's health that is expected to drive future revenue growth and increase market share.
- Clinical Trial Progress: Enrollment in oncology clinical trials is ahead of schedule, with a targeted launch for new products in 2027, prompting management to increase R&D spending by $50 million to accelerate trial timelines, demonstrating confidence in future market opportunities.
- Gross Margin Guidance Raised: Management has raised the gross margin guidance for 2026 to 65%, reflecting an optimistic outlook on revenue growth, despite the rapid increase in volumes in Q1 exerting short-term pressure on margins.
See More
Natera Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Natera reported a Q1 GAAP EPS of -$0.60, missing expectations by $0.05, yet achieved revenue of $696.6 million, reflecting a robust 38.8% year-over-year growth and exceeding market expectations by $79.53 million, indicating strong market performance.
- Testing Volume Growth: The company processed approximately 1,013,600 tests in Q1 2026, an 18.5% increase from about 855,100 tests in Q1 2025, demonstrating sustained demand for its testing services and enhancing its competitive position in the market.
- Oncology Testing Surge: In oncology, approximately 258,900 tests were processed in Q1 2026, up 54.4% from about 167,700 in Q1 2025, showcasing strong growth momentum in this segment and further solidifying Natera's leadership in oncology testing.
- Revenue Guidance Increase: Natera raised its 2026 annual revenue guidance midpoint by $120 million, adjusting the range from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion, reflecting confidence in future performance despite a 1% decline in share price.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
FDA Approves Tecentriq for Bladder Cancer Treatment
- New Indication Approved: The FDA has approved Roche-owned Genentech's Tecentriq (atezolizumab) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC), specifically targeting those with circulating tumor DNA molecular residual disease after cystectomy, marking a significant expansion in cancer treatment applications.
- Companion Diagnostic Approved: The FDA also approved Natera's Signatera CDx as a companion diagnostic for this indication, aimed at identifying ctDNA MRD-positive patients who are likely to benefit from Tecentriq therapy, thereby enhancing treatment precision and effectiveness.
- Increased Indications: Tecentriq now boasts 11 approved indications, demonstrating its broad applicability in oncology and strengthening Roche's competitive position in the oncology market while providing patients with more treatment options.
- Positive Market Outlook: With the expansion of Tecentriq's indications, Roche's market outlook in oncology appears optimistic, expected to drive future sales growth and solidify its leadership position in the biopharmaceutical industry.
See More
Natera Receives FDA Approval for Personalized MRD Testing
- FDA Approval Milestone: Natera's Signatera CDx has received FDA approval as the first personalized molecular residual disease (MRD) test for MIBC patients, marking a new standard in precision cancer treatment that is expected to significantly improve outcomes for MRD-positive patients.
- Clinical Trial Support: The IMvigor011 trial demonstrated that MRD-positive patients treated with immunotherapy achieved significant improvements in disease-free survival (DFS) and overall survival (OS), while MRD-negative patients had a 97% two-year OS without any adjuvant therapy, providing crucial evidence for clinical decision-making.
- Significant Market Potential: With approximately 30,000 new MIBC diagnoses annually in the U.S. and 150,000 globally, the application of Signatera will assist physicians in accurately identifying recurrence risks, optimizing treatment plans, and reducing unnecessary therapies, thereby enhancing patient quality of life.
- Signal of Industry Transformation: This approval not only validates Natera's decade-long vision but also propels the advancement of precision oncology, likely leading to the application of MRD testing across more cancer types, further improving patient treatment outcomes and survival rates.
See More
Natera Reports Q1 Results Exceeding Revenue Expectations with 38.8% Growth
- Significant Revenue Growth: Natera's Q1 revenue reached $696.6 million, reflecting a 38.8% year-over-year increase that surpassed analyst expectations of $613.9 million, indicating strong market demand in women's health and oncology sectors.
- GAAP Loss Exceeds Expectations: Despite robust revenue, Natera reported a GAAP loss of $0.60 per share, which was worse than the anticipated $0.55 loss, leading to a negative market reaction that impacted stock performance.
- Surge in Clinical Testing Demand: Clinical oncology testing volumes grew by 55% year-over-year, driven by strong demand for the Signatera product and increased physician adoption, highlighting the company's competitive position in the cancer detection market.
- Future Growth Potential: Natera plans to launch Signatera in Japan, which is expected to significantly expand its colorectal cancer testing market, while also investing in early detection platforms to drive long-term growth opportunities.
See More
Natera Reports 39% Revenue Growth in Q1 2026
- Significant Revenue Growth: Natera reported $697 million in revenue for Q1 2026, representing a 39% year-over-year increase, highlighting strong performance in women's health and oncology, which further solidifies its market position.
- Surge in Product Orders: The Fetal Focus product is approaching 200,000 orders, marking a successful launch in women's health that is expected to drive future revenue growth and increase market share.
- Clinical Trial Progress: Enrollment in oncology clinical trials is ahead of schedule, with a targeted launch for new products in 2027, prompting management to increase R&D spending by $50 million to accelerate trial timelines, demonstrating confidence in future market opportunities.
- Gross Margin Guidance Raised: Management has raised the gross margin guidance for 2026 to 65%, reflecting an optimistic outlook on revenue growth, despite the rapid increase in volumes in Q1 exerting short-term pressure on margins.
See More
Natera Q1 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Performance: Natera reported a Q1 GAAP EPS of -$0.60, missing expectations by $0.05, yet achieved revenue of $696.6 million, reflecting a robust 38.8% year-over-year growth and exceeding market expectations by $79.53 million, indicating strong market performance.
- Testing Volume Growth: The company processed approximately 1,013,600 tests in Q1 2026, an 18.5% increase from about 855,100 tests in Q1 2025, demonstrating sustained demand for its testing services and enhancing its competitive position in the market.
- Oncology Testing Surge: In oncology, approximately 258,900 tests were processed in Q1 2026, up 54.4% from about 167,700 in Q1 2025, showcasing strong growth momentum in this segment and further solidifying Natera's leadership in oncology testing.
- Revenue Guidance Increase: Natera raised its 2026 annual revenue guidance midpoint by $120 million, adjusting the range from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion, reflecting confidence in future performance despite a 1% decline in share price.
See More
Strait of Hormuz Reopening Boosts Healthcare Stocks
- Oil Price Impact on Healthcare Costs: The reopening of the Strait of Hormuz has led to a decrease in global logistics and energy costs, directly reducing operational expenses for healthcare providers and medical device manufacturers, thereby enhancing profit margins and improving quarterly earnings outlooks.
- Risk Appetite Resurgence: The ceasefire has sparked a 'risk-on' sentiment, driving investors back into high-growth biotech and pharmaceutical stocks, which is expected to facilitate funding for long-term R&D and clinical trials that were previously hindered by macroeconomic uncertainties.
- Reduced Market Volatility: As broader market volatility recedes, investor confidence in elective procedures and pharmaceutical demand strengthens, with expectations that this trend will continue through 2026, further stabilizing the global economy.
- Natera's Stock Volatility: Natera's shares have experienced 13 moves greater than 5% in the past year; today's 5.4% increase indicates market recognition of the news's significance, yet the stock remains down 8.9% year-to-date, trading 18.1% below its 52-week high.
See More
